Tea Tree Oil
ApprovedSmall molecule
Tea Tree Oil is one of 38 small molecule programs targeting Blepharitis. It is currently in Approved.
2
Indications
3
Total Trials
0
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
45 competitors in Gingivitis
#DrugCompanyPhaseTrials
1Flagyl
DDePuy Orthopaedics
Approved
Peridex
DDexcel Pharma Technologies Ltd.
Approved
Cetylpyridinium Chloride
SanofiApproved
Tea Tree Oil
FFederal University of São Paulo
Approved
Triclosan
CColgate Palmolive
Phase 3
Active Comparator
ModernaPhase 2
Negative Control
GSKPhase 3
Test
RRespirent Pharmaceuticals Co Ltd.
Phase 2
Sodium Laural Sulfate
GSKPhase 3
Deltavit
HHyundai Pharmaceutical Co., LTD.
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Healing1 trial
Healing Effect of Tea Tree Oil on Burn
Completed·—·Phase 1·NCT07149844·30 enrolled
Gingivitis1 trial
Clinical and Microbiological Evaluation Of The Efficacy Of Herbal Mouthwashes in Gingivitis
Completed·—·Phase 4·NCT06904742·52 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tea Tree Oil. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- FFederal University of São Paulo